阿托伐他汀对缺血性脑卒中患者血管内皮生长因子和一氧化氮的影响

目的:探讨不同剂量阿托伐他汀对缺血性脑卒中患者血清血管内皮生长因子(VEGF)、一氧化氮(NO)的影响。方法:83例缺血性脑卒中患者随机分为两组:治疗Ⅰ组43例,常规治疗基础上口服阿托伐他汀20 mg/d;治疗Ⅱ组40例,常规治疗基础上口服阿托伐他汀10 mg/d。治疗4周后观察疗效,并测定治疗前、后患者血清VEGF和NO水平的变化。结果:治疗4周后,两组神经功能缺损评分差异有统计学意义(P<0.05);治疗Ⅰ组总有效率(93.0%)明显高于治疗Ⅱ组(80.0%)(P<0.05)。治疗后两组血清VEGF和NO表达均有增强,与治疗前比较差异均有统计学意义(P均<0.05),治疗Ⅰ组提高更为明显,与治疗Ⅱ组比较差异均有统计学意义(P<0.05)。结论:阿托伐他汀20 mg/d可明显提高缺血性脑卒中患者血清VEGF和NO水平,从而达到治疗和预防脑卒中的目的。

Effect of atorvastatin on serum vascular endothelial growth factor and nitric oxide in patients with ischemic stoke

Objective：To investigate the effect of atorvastatin on serum vascular endothelial growth factor（VEGF） and nitric oxide（NO） in patients with ischemic stoke.Methods：A total of 83 patients with ischemic stoke were randomly divided into two groups：Treatment groupⅠ（43 cases）were treated with a basic medicine and atorvastatin 20 mg/d;treatment groupⅡ（40 cases） were treated with a basic medicine and atorvastatin 10mg/d.Therapeutic effect was determined at the end of 4 weeks treatment.The levels of serum VEGF and NO were measured before and after therapy in all patients.Results：The efficacy of the treatment groupⅠat the end of 4 weeks treatment were significantly higher than the treatment groupⅡ（93.0% vs 80.0%）.There were significant differences in two groups（P0.05）.The levels of serum VEGF and NO were obviously elevated after treatment in two groups.There were significant differences compared with before treatment（P0.05）.The levels elevation of serum VEGF and NO in the treatment groupⅠhad a significant difference compared with those in the treatment groupⅡ（P0.05）.Conclusions：Atorvastatin at 20mg/d could dramatically elevate the levels of serum VEGF and NO.It is effective in treatment and prevention for ischemic stoke.